Agios Pharmaceuticals (NASDAQ:AGIO) Given New $38.00 Price Target at Truist Financial

Agios Pharmaceuticals (NASDAQ:AGIO) had its target price lifted by Truist Financial from $32.00 to $38.00 in a report released on Wednesday, MarketBeat Ratings reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts have also weighed in on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday. HC Wainwright decreased their price objective on Agios Pharmaceuticals from $56.00 to $48.00 and set a “buy” rating on the stock in a report on Thursday, November 20th. The Goldman Sachs Group lowered their price objective on Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating for the company in a research report on Thursday, November 20th. Wall Street Zen downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. Finally, Bank of America increased their price target on Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $38.22.

Agios Pharmaceuticals Stock Up 17.5%

Shares of AGIO opened at $28.90 on Wednesday. Agios Pharmaceuticals has a 52-week low of $22.24 and a 52-week high of $46.00. The company has a market capitalization of $1.69 billion, a PE ratio of -4.13 and a beta of 0.87. The stock has a fifty day simple moving average of $34.28 and a two-hundred day simple moving average of $36.31.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, beating the consensus estimate of ($1.93) by $0.15. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The firm had revenue of $12.88 million for the quarter, compared to analysts’ expectations of $10.49 million. During the same quarter in the previous year, the company posted $16.22 EPS. The company’s revenue was up 43.3% compared to the same quarter last year. As a group, equities analysts anticipate that Agios Pharmaceuticals will post -6.85 earnings per share for the current fiscal year.

Insider Activity

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 3,651 shares of the stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $36.77, for a total transaction of $134,247.27. Following the sale, the chief financial officer directly owned 33,870 shares in the company, valued at $1,245,399.90. This represents a 9.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Sarah Gheuens sold 3,302 shares of the firm’s stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $43.92, for a total transaction of $145,023.84. Following the completion of the transaction, the insider directly owned 61,727 shares of the company’s stock, valued at $2,711,049.84. This represents a 5.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 7,553 shares of company stock worth $305,001 in the last three months. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP boosted its stake in shares of Agios Pharmaceuticals by 31.4% in the 2nd quarter. Marshall Wace LLP now owns 684,669 shares of the biopharmaceutical company’s stock valued at $22,772,000 after buying an additional 163,796 shares during the period. Assenagon Asset Management S.A. purchased a new position in Agios Pharmaceuticals in the third quarter worth approximately $2,696,000. Frazier Life Sciences Management L.P. lifted its stake in Agios Pharmaceuticals by 19.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 1,279,754 shares of the biopharmaceutical company’s stock worth $42,565,000 after acquiring an additional 209,900 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Agios Pharmaceuticals by 30.7% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 505,225 shares of the biopharmaceutical company’s stock worth $16,804,000 after acquiring an additional 118,702 shares in the last quarter. Finally, Boothbay Fund Management LLC increased its position in shares of Agios Pharmaceuticals by 71.1% in the 2nd quarter. Boothbay Fund Management LLC now owns 447,019 shares of the biopharmaceutical company’s stock valued at $14,868,000 after purchasing an additional 185,798 shares during the last quarter.

Key Headlines Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: FDA approval of AQVESME (mitapivat) for anemia in adults with alpha‑ and beta‑thalassemia — expands the drug’s U.S. label and establishes mitapivat as the only approved oral option for both non‑transfusion‑dependent and transfusion‑dependent patients. Market reaction: shares jumped premarket and trading was briefly halted for news. GlobeNewswire: FDA Approves AQVESME
• Positive Sentiment: Analysts raised targets and ratings after the approval — Truist raised its price target to $38 (buy) and BofA raised its target to $34 (buy), signaling institutional optimism on commercial prospects. Truist / The Fly
• Positive Sentiment: Company financial/capital position supports commercialization — analysts note a strong cash runway (cited ~$1.3B cash vs ~$101M liabilities) which reduces near‑term financing risk for launch and commercialization activities. Seeking Alpha: Investment note
• Neutral Sentiment: AQVESME commercial launch timing and pricing: company expects U.S. availability in late January 2026, and media reports cite a list‑price approximation (~$425k per patient/year) — positive for revenue per patient but could raise payer/access questions. MSN: Pricing report
• Neutral Sentiment: Market commentary flags peak‑sales ceiling — some analysts estimate thalassemia sales potential in the mid‑hundreds of millions (cited ~ $500M peak), implying the approval alone may not drive profitability; sickle cell disease (SCD) approval would be a larger long‑term catalyst. Seeking Alpha: Commercial outlook
• Negative Sentiment: Label includes a REMS/boxed warning for liver injury — regulators required risk‑management measures which may complicate prescribing, monitoring and patient uptake and could temper near‑term adoption. Zacks: REMS in label
• Neutral Sentiment: Short‑interest data posted for December appears inconsistent/insignificant in filings (zero reported), so short‑covering is unlikely to be a clear driver. Reuters: market reaction

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.